Fusion Pharmaceuticals Inc.
Records under this name other than the patents Fusion Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Fusion Pharmaceuticals Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,191,854 | Pharmacokinetic Enhancements of Bifunctional Chelates and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,093,741 | IGF-1R Monoclonal Antibodies and Uses Thereof Lapsed on the fee record Ended Oct 9, 2026 · High confidence | Lapsed on the fee record | Ended Oct 9, 2026 | High confidence |
| US 11,318,210 | Endosialin-Binding Antibody Lapsed on the fee record Ended May 3, 2026 · High confidence | Lapsed on the fee record | Ended May 3, 2026 | High confidence |
| 15/048,030 | FGFR3 and PD1 Inhibitory Compositions and Associated Methods of Use for Treating Cancer Abandoned Abandoned Oct 8, 2022 | Abandoned | Abandoned Oct 8, 2022 | |
| 15/890,278 | Methods, Compositions, and Kits for Treatment of Cancer Abandoned Abandoned Jun 5, 2020 | Abandoned | Abandoned Jun 5, 2020 | |
| 16/619,433 | Radioimmunoconjugates and DNA Damage and Repair Inhibitor Combination Therapy Abandoned Abandoned Oct 17, 2026 | Abandoned | Abandoned Oct 17, 2026 | |
| 16/805,508 | Methods and Compositions for Treating Cancer Abandoned Abandoned Nov 30, 2022 | Abandoned | Abandoned Nov 30, 2022 | |
| 16/859,006 | Methods, Compositions, and Kits for Treatment of Cancer Abandoned Abandoned Oct 29, 2021 | Abandoned | Abandoned Oct 29, 2021 | |
| 17/045,320 | HSP90-Targeting Conjugates and Formulations Thereof Abandoned Abandoned Feb 22, 2025 | Abandoned | Abandoned Feb 22, 2025 | |
| 17/272,129 | Macrocyclic Chelates and Uses Thereof Abandoned Abandoned Sep 4, 2025 | Abandoned | Abandoned Sep 4, 2025 |